Glucose-lowering effects of incretin-based therapies

Journal of Family Practice

Volumn 59, Issue 9 SUPPL. 1, 2010, Pages

  Campbell, R Keith ^a   Cobble, Michael E ^b,c   Reid, Timothy S ^d   Shomali, Mansur E ^e,f  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Canyons Medical Center   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d Mercy Diabetes Center   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f UNION MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 AGONIST; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; DRUG DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; GLYCOSYLATED HEMOGLOBIN; PEPTIDE; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; VENOM;

ADD ON THERAPY; ALGORITHM; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE KIDNEY FUNCTION RELATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FRACTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; SIDE EFFECT; WEIGHT GAIN; AGED; CASE REPORT; DRUG POTENTIATION; FEMALE; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY;

ADAMANTANE; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; PYRAZINES; RECEPTORS, GLUCAGON; TRIAZOLES; VENOMS;

EID: 77956708655     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
2. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
3. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:376-386. (Pubitemid 351524285)
4. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
5. Rodbard HW, Jellinger PS, Davidson JA, et al. American Association of Clinical Endocrinologists/American College of Endocrinology. AACE/ACE diabetes algorithm for glycemic control (update). http://www.aace.com/pub/pdf/ GlycemicControlAlgorithmPPT.pdf. Published 2009. Accessed May 17, 2010.
6. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881-885. (Pubitemid 36929359)
7. Fuller JH, Shipley MJ, Rose G, et al. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet. 1980; 1:1373-1376.
8. Beks PJ, Mackaay AJC, de Neeling JND, et al. Peripheral arterial disease in relation to glycaemic level in an elderly caucasian population. The Hoorn Study. Diabetologia. 1995;38:86-96.
9. Fontbonne AM, Eschwège EM. Insulin and cardiovascular disease. Paris Prospective Study. Diabetes Care. 1991;14:461-469.
10. Donahue RP, Abbott RD, Reed DM, et al. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987;36:689-692.
11. DECODE Study Group. European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and ADA diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617-621.
12. Hanefeld M, Fischer S, Julius U, et al; for the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583.
13. McMurray JJ, Holman RR, Haffner SJ, et al; and the NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. New Engl J Med. 2010;362:1463-1476.
14. Nathan DM. Navigating the choices for diabetes prevention. New Engl J Med. 2010;362:1533-1535.
15. Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2009.
16. Victoza [package insert]. Princeton, NJ: Novo Nordisk Inc; 2010.
17. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; February 26, 2010.
18. Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
19. Januvia. Supplement approval. US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2010/ 021995s010s011s012s014ltr.pdf. Published 2010. Accessed June 7, 2010.
20. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(suppl 1): S11-S61.
21. Nelson P, Poon T, Guan X, et al. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther. 2007;9:317-326. (Pubitemid 47340082)
22. Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30:1448-1460.
23. Vilsboll T, Zdravkovic M, Le Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608-1610. (Pubitemid 46871185)
24. Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61:171-180. (Pubitemid 46269371)
25. Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23:1329-1339. (Pubitemid 46998442)
26. Vilsboll T, Krarup T, Madsbad S, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002;45:1111-1119. (Pubitemid 34985287)
27. Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301-307. (Pubitemid 23037285)
28. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-830. (Pubitemid 34233752)
29. Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes. 1998;47:764-769.
30. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632-2637. (Pubitemid 44912190)
31. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100. (Pubitemid 40616618)
32. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333-2348. (Pubitemid 350298125)
33. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
34. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638-2643. (Pubitemid 44912191)
35. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24:537-550. (Pubitemid 351294402)
36. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009;32:1649-1655.
37. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
38. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-dairy liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33:1300-1303.
39. DeFronzo RA, Okerson T, Viswanathan P, et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943-2952.
40. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-1456.
41. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091. (Pubitemid 40616617)
42. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436-447.
43. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259-267.
44. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-569.
45. Zinman B, Hoogwerf BJ, Duran GS, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146:477-485. (Pubitemid 351650556)
46. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia. 2009;52:2046-2055.
47. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224-1230.
48. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733-745. (Pubitemid 47261855)
49. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278.
50. Rosenstock I, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidases inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556-1568. (Pubitemid 44841980)
51. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:4810-4819.
52. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63:1395-1406.